Vaccinex Inc.

NASDAQ: VCNXHealthcare / Biotechnology / USA
5.25-0.0700-1.32%Vol 2 8511Y Perf -53.87%
Jun 24th, 2019 14:22
BID5.05 ASK5.30
Open5.20 Previous Close5.32
Pre-Market- After-Trading-
 - -%  - -%
Target Price
22.00 
Analyst Rating
— — 0.00
Potencial %
319.05 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)60 
Earnings Rating
Price Range Ratio 52wk %
22.24 
Earnings Date
12th Jun 2019

Today's Price Range

5.105.25

52wk Range

3.3212.00

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Month
-21.80%
3 Months
7.93%
6 Months
18.00%
1 Year
-53.87%
3 Years
-
5 Years
-

Name / TickerPriceChg.Chg.%
VCNX5.25-0.0700-1.32
AAPL198.58-0.2000-0.10
GOOG1 115.52-6.3600-0.57
MSFT137.780.81000.59
XOM76.95-0.7400-0.95
WFC46.27-0.6200-1.32
JNJ143.060.97000.68
FB192.601.46000.76
GE10.28-0.2000-1.91
JPM108.66-0.7800-0.71
Earnings HistoryEstimateReportedSurprise %
Q01 2019-0.68-0.79-16.18
Q03 2018-0.58-0.93-60.34
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.68
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume2 851
Shares Outstanding (in ths.)11 479
Trades Count14
Dollar Volume12 167
Avg. Volume10 694
Avg. Weekly Volume7 059
Avg. Monthly Volume9 140
Avg. Quarterly Volume13 078
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Rating---

Vaccinex Inc.

Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its lead product candidate VX15 is in clinical development for the treatment of NSCLC, osteosarcoma and Huntington's disease and additional product candidates VX5 and VX25 are in earlier stages of development.

CEO: Maurice Zauderer

Teplephone: +1 585 271-2700

Address: 1895 Mount Hope Avenue, Rochester 14620, NY, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

71%29%

Bearish Bullish

44%56%

Bearish Bullish

50%50%

News